Why Is ARTL Stock Soaring Pre-Market Today?
Synopsis
Artelo Biosciences secured a fully-funded study to evaluate the effects of its peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.
Artelo Biosciences Inc. (ARTL) on Wednesday announced that it has secured a fully funded glaucoma study following an agreement with Glaucoma UK and the HSC R&D Division.
The study will evaluate the effects of Artelo’s peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.
Artelo Biosciences shares were up more than 40% in Wednesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory with message volumes at ‘high’ levels at the time of writing.
Get updates to this story developing directly on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.